The efficacy of COVID-19 vaccines against the B.1.617.2 (delta) variant

Cai, Changjing; Liu, Yihan; Zeng, Shan; Shen, Hong; Han, Yangyang

doi:10.1016/j.ymthe.2021.09.024

Cited by 18 publications

(20 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…None of the vaccinated healthcare workers who acquired COVID-19 required hospitalization or developed severe disease, which is consistent with other studies conducted before and after the Delta variant became dominant. 3,4 Our data suggests that the Delta variant has impacted the attack rate following household exposure of healthcare providers compared to previous SARS-CoV-2 variants, even after HCW were fully vaccinated. Spousal relationship has previously been shown to be a high risk for secondary infection, with a mean household secondary attack rate of spouses of 37.8% in prevaccination data .…”

mentioning

confidence: 79%

Increase in the coronavirus disease 2019 (COVID-19) attack rate of fully vaccinated healthcare workers with high-risk household exposures correlates with the rise of the severe acute respiratory coronavirus virus 2 (SARS-CoV-2) B.1.617.2 (delta) variant

Selby

Hewlett

Rupp

et al. 2022

Infect. Control Hosp. Epidemiol.

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 79%

Increase in the coronavirus disease 2019 (COVID-19) attack rate of fully vaccinated healthcare workers with high-risk household exposures correlates with the rise of the severe acute respiratory coronavirus virus 2 (SARS-CoV-2) B.1.617.2 (delta) variant

Selby

Hewlett

Rupp

et al. 2022

Infect. Control Hosp. Epidemiol.

View full text Add to dashboard Cite

show abstract

“…The previous study had proved that vaccines induce neutralizing antibodies and block the viral receptor binding domain from binding to the angiotensin-converting enzyme 2 receptors. Against the emerging VOCs, such as the Delta variant, although vaccine showed a reduction in its efficacy, it still protected the patients as human proper T cell can rapidly respond to the virus spike protein when prevaccinated ( 2 , 6 ). The results of this study may be explained by the abovementioned mechanism.…”

Section: Discussionmentioning

confidence: 99%

“…Vaccination has also been approved, and the national immunization campaign has been conducted since the late 2020. The efficacy of all vaccines is ∼70%; the mRNA vaccines have even up to 95% protective rate against COVID-19 ( 1 , 2 , 8 ).…”

Section: Introductionmentioning

confidence: 99%

Clinical Characteristics of COVID-19 Patients' Postvaccination

et al. 2022

View full text Add to dashboard Cite

To investigate the clinical characteristic of domestic coronavirus disease 2019 (COVID-19) patients after vaccination campaign conducted in China. According to vaccination status and months from first vaccine dose to infection detection, patients were divided into unvaccinated, <3 months, 3–6 months, and >6 months groups. The information of demographic and clinical characteristics, laboratory and thoracic computed tomography (CT) findings, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid and IgM, IgG antibodies was retrospectively collected. Therapeutic approaches, temperature-normalizing and viral shedding times, outcomes were also summarized. SARS-CoV-2 antibody levels were further analyzed based on the other following variables: time from second vaccine dose to infection, vaccine dose, the interval from the first to the second dose, and vaccine brand. Among 208 COVID-19 patients, 13 (6.28%) were unvaccinated. No significant differences in demographic and clinical characteristics, laboratory and CT findings, and SARS-CoV-2 nucleic acid loads were detected between groups (all p > 0.05). In comparison with the unvaccinated group, the median SARS-CoV-2 IgG levels were noticeably increased in those vaccinated groups (0.603 in unvaccinated, 15.925 in <3 months, 14.04 in 3–6 months, and 4.94 in >6 months, respectively, p < 0.05). However, SARS-CoV-2 IgG levels were not altered between groups divided based on the other variables. Vaccination does not affect the clinical characteristics in COVID-19 patients. COVID-19 patients with vaccination have high SARS-CoV-2 IgG levels. Underscore the necessity of rapid implementation of vaccination campaigns can be speculated.

show abstract

“…Indeed, one large concern regarding the efficacy of currently distributed vaccines is how efficacious they are to providing protection against infection from new variants. A study demonstrated that while vaccines did not completed prevent infection by the COVID-19 delta variant, mRNA based vaccines were more efficacious at proving protecting against moderate and severe infection ( 87 ).…”

Section: Vaccine Developmentmentioning

confidence: 99%

Understanding COVID-19: From Dysregulated Immunity to Vaccination Status Quo

2021

View full text Add to dashboard Cite

The development of vaccines against infectious diseases has helped us battle the greatest threat to public health. With the emergence of novel viruses, targeted immunotherapeutics ranging from informed vaccine development to personalized medicine may be the very thing that separates us between life and death. Late in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of coronavirus disease 2019 (COVID-19), made a remarkable entrance to human civilization, being one of many to cross the species barrier. This review discusses the important aspects of COVID-19, providing a brief overview of our current understanding of dysregulated immune responses developed using various experimental models, a brief outline of experimental models of COVID-19 and more importantly, the rapid development of vaccines against COVID-19.

show abstract

The efficacy of COVID-19 vaccines against the B.1.617.2 (delta) variant

Cited by 18 publications

References 15 publications

Increase in the coronavirus disease 2019 (COVID-19) attack rate of fully vaccinated healthcare workers with high-risk household exposures correlates with the rise of the severe acute respiratory coronavirus virus 2 (SARS-CoV-2) B.1.617.2 (delta) variant

Increase in the coronavirus disease 2019 (COVID-19) attack rate of fully vaccinated healthcare workers with high-risk household exposures correlates with the rise of the severe acute respiratory coronavirus virus 2 (SARS-CoV-2) B.1.617.2 (delta) variant

Clinical Characteristics of COVID-19 Patients' Postvaccination

Understanding COVID-19: From Dysregulated Immunity to Vaccination Status Quo

Contact Info

Product

Resources

About